ABOUT TERUMO
The field of cell therapy is a fast-moving, ever-changing landscape. We take pride in leading the way with comprehensive manufacturing strategies, customized solutions and performance-focused products, all backed with the expertise and support to help guide your success.
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.
Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 130 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.
We have global headquarters in Lakewood, Colo., U.S.A., along with five regional headquarters, seven manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.
VIDEOS
-
How Terumo Blood And Cell Technologies' Are Advancing Cell and Gene Therapies
Learn more about the to development of patient-centric innovations to help revolutionize health care and improve clinical outcomes.
-
Fill And Finish: Automated Vs Manual
You've invested a great deal to get your cells to the fill and finish stage. See how see how automating fill and finish reduces risk at this critical step.
-
Finia Fill And Finish
Finia is the first of its kind to automate final formulation and fill and finish for cell therapy manufacturing.
-
Finia Facts - Reduce The Risk Of Fill And Finish – Remaining Compliant
Minimize errors. Meet compliance requirements. Learn how the Finia Fill and Finish System automates data capture to facilitate cGMP compliance.
-
Finia Facts - Reduce The Risk Of Fill And Finish – Operator And Product Variability
Minimize your variability. Maximize your viability. Optimize your process and ensure product consistency with the Finia Fill and Finish System.
-
Reduce The Risk Of Fill And Finish – Minimizing Open Events
Minimize your risk. Maximize your returns. Get your product to those who need it most, when they need it most with the Finia Fill and Finish System.
-
Health Economics And Finia Fill And Finish System
In our new video series, Teru Talks, our experts discuss their points of view on current industry trends, challenges, and opportunities. In our first episode, we’ll discuss the topic of health economics and how it can apply to your business.
CONTACT INFORMATION
Terumo BCT
10810 West Collins Avenue
Lakewood, CO 80215
UNITED STATES
Phone: 877-339-4228
FEATURED WEBINARS
-
Elevate Your T-Cell Manufacturing Process
-
Efficient And Effective T-Cell Expansion In A Hollow-Fiber Perfusion System
-
Automated Stem Cell Manufacturing: The Experience At An Academic Center
BROCHURES
- Where Cells Thrive
- Quantum Flex Cell Expansion Platform
- Quantum Flex: Where Cells Thrive
- Quantum Flex: The Next Generation Of Cell Expansion
- StafaCT Suite
- SPECTRA OPTIA® Apheresis System
- QUANTUM® Cell Expansion System
- FINIA® Fill and Finish System
FEATURED ARTICLES
-
Ways To Enhance Access To Cell Therapies
Cell therapies are revolutionizing cancer care, but their complex manufacturing and high costs bar access for many patients. Automation is emerging as an efficacious solution to reach patients in need.
-
Expansion Of Cord Blood-Derived CD34+ Cells In A Hollow-Fiber Bioreactor With 10% Standard Cytokine Concentration
CD34+ cells isolated from cord blood were expanded in a hollow-fiber bioreactor using a novel cytokine cocktail at one-tenth the standard concentration using a MSC-free coating strategy.
-
Navigating The Challenges Of Bringing Cell And Gene Therapies To Market
Cell and gene therapies are witnessing rapid advancements, but significant challenges remain for their commercialization due to regulatory hurdles, manufacturing barriers, high costs, and safety concerns.
-
T-Cell Manufacturing: When Is The Right Time To Automate?
Automation enhances efficiency and minimizes contamination risks and labor costs. Despite the initial investment in automation equipment, the long-term savings can be significant.
-
How Cell And Gene Therapies Are Evolving
Advances in manufacturing technologies and equipment are improving the efficiency and reproducibility of cell and gene therapies and helping overcome the current supply and demand imbalance.
-
Harnessing The Power Of Cell And Gene Therapy In Oncology
Advances in oncology, specifically in CAR T-cell therapies and TILs, are leading the way in cell and gene therapy. However, costs and complex regulations present challenges.
-
Quality Versus Quantity In T-Cell Production
Technological advances have made it possible to produce high-quality T cells at scale, providing a boon for T-cell manufacturing.
-
iPSC Expansion In A Cell Expansion System's Small Bioreactor
Explore how using a flexible, automated system can help expand induced pluripotent stem cells (iPSCs) faster than traditional culture methods.
-
Cell Expansion System Supports Proliferation Of Regulatory T-Cells
This study showcases a cell expansion system that is providing T-cells with an ideal environment for growth, efficient in expanding many cells quickly, and enhancing regulatory T-cell characteristics.
-
HEK293T Cell Expansion Protocol Using A Hollow-Fiber Bioreactor System
Explore the use of a hollow-fiber bioreactor (HFB) system for the automated expansion of HEK293T cells and a protocol used to help users of the system.
-
Study Of Small Bioreactor Expansion Kinetics During Expansion Protocol
Mesenchymal stem cells have been used to show equivalent expansion kinetics during a 7-day expansion protocol on both the small and standard bioreactors revealing efficiency differences.
-
Quintessential Role Of Apheresis In Gene-Modified T-Cell Therapy
Learn more about process standardization and comprehensive quality management programs as it relates to leukapheresis and cell therapy manufacturers.
-
Choose The Right Bioreactor Size For Your Cell Expansion
Compare expansion parameters when adherent cells are cultured on the small and standard bioreactors using a hollow-fiber bioreactor platform.
-
Optimized Fill And Finish To Limit DMSO's Negative Impact On T Cells
In order to improve the existing cryopreservation paradigm, operators must consider fill/finish and cryopreservation techniques that streamline processing steps and minimize cells’ exposure to DMSO.
-
Matters of Scale: Centralized vs. Decentralized Manufacturing Of Advanced Therapies
Reducing human intervention and manual processes in advanced therapy manufacturing is critical to improving a manufacturing paradigm, safeguarding quality, simplifying processes, and improving efficacy.
-
Elevate Your T-Cell Manufacturing Process
Today automation and next-generation bioreactors are two prime areas of innovation for enhancing cell manufacturing. Here we delve into some ways these innovations could improve T-cell based therapy production.
-
The Monoculture Of Cord-Blood-Derived CD34+ Cells
Explore an 8-day expansion of a 2 × 10 positively selected CD34+ cell inoculum from 3 donor lineages, and the results proving the automated monoculture protocol can support that expansion with minimal lymphocyte residual.
-
Incorporating Automation Into Your Fill And Finish Procedure
Incorporate automation into fill and finish procedures and learn more about the impact of automation on production costs and product quality.
-
Cell Therapy's Live Analytical Challenges
Learn about analytical science tools that can be employed to take cell and gene therapy to the next level.
-
Achieve Efficiency And Quality In Cell Therapy Manufacturing
Enabling automation, reducing manual steps, and implementing standard procedures is key to success in cell therapy manufacturing.
NEWS
- Terumo Blood And Cell Technologies Launches Study With BioCentriq® To Generate Public CAR-T Cell Data Using Terumo BCT's CGT Manufacturing Platforms
- Terumo Blood And Cell Technologies Launches Quantum Flex Bioreactor Platform, One Of The First Systems That Enables Cell Therapy Commercialization From Process Development Through Manufacturing
- Terumo Blood And Cell Technologies And GenCure Collaborate To Advance Cell And Gene Therapy Manufacturing Solutions
FEATURED PRODUCTS
- Quantum Flex Cell Expansion System
- Automate Your Fill and Finish Process for Precision